Freedom of information requests

Patients with acute myeloid leukaemia (AML)

Questions

Patients with acute myeloid leukaemia (AML)

 

1. How many patients have received treatment with venetoclax for AML during the past 24 months? Note: please provide data for the most recent 24-month period available via your prescribing/management system.

 

2. What is the average daily dose (mg) for AML patients receiving venetoclax during the past 24 months?

 

3. What is the average duration of treatment (months) for AML patients receiving venetoclax during the past 24 months?

 

4. What is the average duration of treatment (months) for AML patients receiving venetoclax during the past 24 months?

 

Patients with chronic lymphocytic leukaemia (CLL)

 

5.  Please complete the table below based on the number of patients that have received venetoclax in each of the specified regimens for CLL in the last 24 months.
Note: please provide data for the most recent 24-month period available via your prescribing/management system.

 

	Treatment regimens
	Venetoclax + obinutuzumab	Venetoclax + rituximab	Venetoclax monotherapy
Total number of CLL patients receiving this treatment regimen during the past 24 months
Average daily maintenance dose (mg) of venetoclax for patients initiated on this regimen during the past 24 months*
Average duration (months) of venetoclax treatment for patients initiated on this regimen during the past 24 months

*We would like to understand the average daily dose of venetoclax in CLL patients during maintenance treatment i.e. after the initial 8-week period during which patients would be receiving a titration regimen.

 

Patients with acute myeloid leukaemia (AML) or chronic lymphocytic leukaemia (CLL)

 

6. Please complete the table below with the average number of venetoclax 10 mg x 14 tablet packs† used per AML or CLL patient receiving each of the specified regimens during the past 24 months.

 

	AML treatment regimen	CLL treatment regimens
	Venetoclax + azacitidine	Venetoclax + obinutuzumab	Venetoclax + rituximab	Venetoclax monotherapy
Average number of venetoclax 10 mg x 14 tablet packs used per patient in each treatment regimen during the past 24 months

†Note: There are five different pack sizes of venetoclax available in the UK:

• Pack 1: venetoclax 10 mg x 14 tablets
• Pack 2: venetoclax 50 mg x 7 tablets
• Pack 3: venetoclax 100 mg x 7 tablets
• Pack 4: venetoclax 100 mg x 14 tablets
• Pack 5: venetoclax 100 mg x 112 tablets

 

7.  Please can you share your prescribing protocol(s) for venetoclax in AML and CLL?

Response

1.  36

2.  Data is not obtainable.

3.  Data is not obtainable.

4.  Data is not obtainable.

5.  

	Treatment regimens
	Venetoclax + obinutuzumab	Venetoclax + rituximab	Venetoclax monotherapy
Total number of CLL patients receiving this treatment regimen during the past 24 months	2	0	11
Average daily maintenance dose (mg) of venetoclax for patients initiated on this regimen during the past 24 months*	Data is not obtainable.	Data is not obtainable.	Data is not obtainable.
Average duration (months) of venetoclax treatment for patients initiated on this regimen during the past 24 months	Data is not obtainable.	Data is not obtainable.	Data is not obtainable.

 

6. 

 

	AML treatment regimen	CLL treatment regimens
	Venetoclax + azacitidine	Venetoclax + obinutuzumab	Venetoclax + rituximab	Venetoclax monotherapy
Average number of venetoclax 10 mg x 14 tablet packs used per patient in each treatment regimen during the past 24 months	Data is not obtainable.	Data is not obtainable.	Data is not obtainable.	Data is not obtainable.